Paraneoplastic syndromes in ophthalmology.

Area of Science:

• Ophthalmology
• Oncology
• Immunology

Background:

• Paraneoplastic syndromes manifest as systemic effects of cancer, not directly from tumor invasion.
• Autoimmunity and autoantibody synthesis, driven by molecular mimicry, are key to their pathophysiology.
• Ophthalmologic paraneoplastic syndromes are rare but clinically significant, sometimes preceding cancer diagnosis.

Purpose of the Study:

• To review the pathophysiology, clinical presentation, and management of paraneoplastic syndromes affecting the visual system.
• To highlight the association between specific cancers and ocular manifestations.
• To emphasize the importance of early diagnosis and multidisciplinary care.

Main Methods:

• Literature review of paraneoplastic syndromes with ocular involvement.
• Analysis of associated cancer types, particularly small cell lung carcinoma.
• Categorization of syndromes based on affected visual pathway (afferent vs. efferent).

Main Results:

• Ocular paraneoplastic syndromes involve afferent pathways (e.g., cancer-associated retinopathy) and efferent pathways (e.g., Myasthenia Gravis).
• Commonly associated cancers include small cell lung carcinoma, thymoma, gynecological tumors, and neuroblastoma.
• Autoantibody presence aids diagnosis, but negativity does not rule out the condition.

Conclusions:

• Paraneoplastic syndromes require careful clinical recognition due to their association with underlying malignancies.
• Management is often linked to the primary cancer, with immunosuppressive therapy potentially improving quality of life.
• Prompt diagnosis and treatment are essential for managing these complex conditions.